Nivolumab Combinations Debated for a Patient With Metastatic Melanoma
Source: Targeted Oncology, August 2024
During a Case-Based Roundtable® event, Hussein A. Tawbi, MD, PhD, and participants considered nivolumab/ipilimumab and nivolumab/relatlimab as options for a patient with metastatic melanoma in the first article of a 2-part series.
CASE SUMMARY
- Twelve years ago, a 78-year-old man with a history of stage III melanoma underwent surgical resection.
- Lymph node density (LND): positive for nodal involvement
- The patient declined complete LND and adjuvant systemic therapy.
- He remained active since his surgery and maintains regular follow-up.
- On present-day routine follow-up, the patient presented with moderate asthenia that is limiting his daily activities, without other relevant clinical symptoms.
- ECOG performance status: 1
- Physical examination: unremarkable
- Notable laboratory findings: lactate dehydrogenase 380 UI/L (reference range, 110-240)
- Full-body CT scan revealed the presence of pulmonary and hepatic nodules, no evidence of brain metastases.
- He underwent core-needle biopsy of the largest hepatic lesion in segment IVb without any complications.
- Pathology revealed metastatic melanoma.
- Mutation testing: BRAF negative